CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($) $ in Millions		Total	Share Repurchase Program	Common Stock	Treasury Stock	Treasury Stock Share Repurchase Program	Additional Paid-in Capital	Additional Paid-in Capital Share Repurchase Program	Retained Earnings	Retained Earnings Share Repurchase Program	Accumulated Other Comprehensive Loss	Equity Attributable to Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2021				501,900,000
Beginning balance at Dec. 31, 2021		$ 4,544		$ 5	$ (2,952)		$ 1,068		$ 7,186		$ (764)	$ 1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		1,651							1,653			(2)
Other comprehensive income/(loss), net of tax		(45)									(45)
Treasury stock, beginning balance (in shares) at Dec. 31, 2021					29,300,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock acquired, shares					(6,700,000)	(600,000)
Share-based compensation awards		5			$ 2		3		0
Treasury stock acquired		(1,189)			(1,189)
Employee benefit plan contribution from Pfizer Inc.	[1]	2					2
Dividends, Common Stock		(306)							(306)
Ending balance (in shares) at Sep. 30, 2022				501,900,000
Ending balance at Sep. 30, 2022		4,662		$ 5	$ (4,139)		1,073		8,533		(809)	(1)
Treasury stock, ending balance (in shares) at Sep. 30, 2022					35,400,000
Beginning balance (in shares) at Jun. 30, 2022				501,900,000
Beginning balance at Jun. 30, 2022		4,580		$ 5	$ (3,766)		1,059		8,004		(722)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		528							529			(1)
Other comprehensive income/(loss), net of tax		(87)									(87)
Treasury stock, beginning balance (in shares) at Jun. 30, 2022					33,300,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock acquired, shares					(2,200,000)	100,000
Share-based compensation awards			$ 17			$ 4		$ 13
Treasury stock acquired		(377)			$ 377
Employee benefit plan contribution from Pfizer Inc.		1					1
Ending balance (in shares) at Sep. 30, 2022				501,900,000
Ending balance at Sep. 30, 2022		$ 4,662		$ 5	$ (4,139)		1,073		8,533		(809)	(1)
Treasury stock, ending balance (in shares) at Sep. 30, 2022					35,400,000
Beginning balance (in shares) at Dec. 31, 2022		501,891,243		501,900,000
Beginning balance at Dec. 31, 2022		$ 4,403		$ 5	$ (4,539)		1,088		8,668		(817)	(2)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		1,817							1,819			(2)
Other comprehensive income/(loss), net of tax		$ 3									3
Treasury stock, beginning balance (in shares) at Dec. 31, 2022		38,083,184			38,100,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock acquired, shares					(5,000,000.0)	(700,000)
Share-based compensation awards		$ 61			$ 34		28		(1)
Treasury stock acquired		(864)			(864)
Dividends, Common Stock		$ (346)							(346)
Ending balance (in shares) at Sep. 30, 2023		501,891,243		501,900,000
Ending balance at Sep. 30, 2023		$ 5,074		$ 5	$ (5,369)		1,116		10,140		(814)	(4)
Treasury stock, ending balance (in shares) at Sep. 30, 2023		42,366,530			42,400,000
Beginning balance (in shares) at Jun. 30, 2023				501,900,000
Beginning balance at Jun. 30, 2023		$ 4,621		$ 5	$ (5,126)		1,098		9,543		(895)	(4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		596							596			0
Other comprehensive income/(loss), net of tax		81									81
Treasury stock, beginning balance (in shares) at Jun. 30, 2023					41,200,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock acquired, shares					(1,400,000)	200,000
Share-based compensation awards			$ 28			$ 9		$ 18		$ 1
Treasury stock acquired		$ (252)			$ 252
Ending balance (in shares) at Sep. 30, 2023		501,891,243		501,900,000
Ending balance at Sep. 30, 2023		$ 5,074		$ 5	$ (5,369)		$ 1,116		$ 10,140		$ (814)	$ (4)
Treasury stock, ending balance (in shares) at Sep. 30, 2023		42,366,530			42,400,000

[1] Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans.